Explore Fear & Greed indicators derived from media coverage across economies and asset classes.
If you are interested in our products, want to see one of our data samples, please leave your email below.
AI-derived sentiment indicator based on analysis of public internet content using artificial intelligence agents discussing AstraZeneca earnings and pharma pipelines.
There is a rush for the second dose of AstraZeneca reported on August 17, 2021.
AstraZeneca's COPD drug, Tozorakimab, has delivered strong study data, achieving an important main goal by cutting COPD flare-ups in late-stage trials.
AstraZeneca's COPD drug demonstrates robust outcomes in significant trials.
Jacobio secures a US$100 million upfront payment from AstraZeneca for their Pan-KRAS cancer drug. There is an update on the administration of the second dose of AstraZeneca.
Jacobio secures a US$100 million upfront payment from AstraZeneca for their Pan-KRAS cancer drug.
AstraZeneca's access to the $5 billion COPD market is data-dependent, according to Bloomberg Intelligence.
The Saudi Medicines Authority is in discussions with AstraZeneca to enhance industry localization in Saudi Arabia and support expansion in African markets.
The Medicines Authority is in discussions with AstraZeneca to enhance industry localization in Egypt and support expansion in African markets.
AstraZeneca will supply the EU with 9 million more corona vaccines.
AstraZeneca's stock jumps after a surprise trial win for their lung disease drug, outperforming rivals who have previously failed in this area.